This is a phase 2, open-label trial designed to evaluate the safety, tolerability, biologic activity, and preliminary efficacy of intratumoral SD 101 injections in combination with Keytruda (pembrolizumab) in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
This study is enrolling patient who have not yet received Keytruda or other anti-PD1 therapy and patients whose disease has progressed while receiving Keytruda or other anti-PD1 therapy.
